Arthur Franken joined Gilde in 2001 and was part of the founding team of Gilde Healthcare. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics (acquired by Zambon), Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), Noema Pharma, ProQR Therapeutics (IPO on NASDAQ), SpliceBio and STAT-Dx (acquired by QIAGEN). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext, acquired by Sanofi-Aventis), Agendia, Amphista Therapeutics, Axonics (IPO on NASDAQ), Calypso Biotech, Eargo (IPO on NASDAQ), uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ), CVRx (IPO on NASDAQ), FIRE1 and Pieris (IPO on NASDAQ).
He represents Gilde on the boards of Calypso, Levicept, Moximed, Noema Pharma and SpliceBio and served as a board member for Breath Therapeutics, FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO.
Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a master’s degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.
